Skip to main content
. 2019 Feb 18;11:1623–1629. doi: 10.2147/CMAR.S188551

Figure 3.

Figure 3

Correlation between median OS and PFS in NSCLC patients who received ICIs.

Abbreviations: ICI, immune checkpoint inhibitor; NSCLC, non-small-cell lung cancer; OS, overall survival; PFS, progression-free survival.